Mawer Investment Management Ltd. Grows Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mawer Investment Management Ltd. lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 256,927 shares of the medical research company’s stock after purchasing an additional 39,042 shares during the quarter. Mawer Investment Management Ltd. owned about 0.92% of Bio-Rad Laboratories worth $84,403,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC increased its stake in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after acquiring an additional 87 shares during the last quarter. Picton Mahoney Asset Management grew its holdings in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock worth $32,000 after purchasing an additional 35 shares in the last quarter. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories in the fourth quarter worth approximately $33,000. UMB Bank n.a. raised its stake in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at approximately $38,000. Institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $243.33 on Friday. The company’s fifty day moving average is $293.54 and its 200 day moving average is $322.48. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52 week low of $241.87 and a 52 week high of $387.99. The stock has a market cap of $6.82 billion, a PE ratio of -3.74 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.